Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Germany Policy Diagnostics

More German Companies Get To Work On COVID-19 Diagnostic Test Development

  • News

Executive Summary

Another three in vitro diagnostics companies in Germany are working on tests for the early detection of COVID-19, with confirmed infections reaching 89,000 globally by 2 March.

You may also be interested in...



COVID-19 Fact File: Global Diagnostic Test Pipeline

Medtech Insight is tracking the IVD companies manufacturing tests for SARS-CoV-2, the coronavirus that causes COVID-19.

NeuMoDx Molecular Launches Coronavirus Test

NeuMoDx Molecular announced plans to develop a coronavirus test for its own high-throughput molecular diagnostics platform.

LabCorp Launches COVID-19 Testing, Quest Diagnostics Will Provide Testing Starting 9 March In US

LabCorp and Quest announced they will offer testing to detect COVID-19 to address the public health crisis.

Table

View full table

Related Content

Medtech Insight

Topics

Related Companies

Tags:
Germany Policy Diagnostics
Latest Headlines

Mosie Baby First To Win FDA Clearance For At-Home DYI Artificial Insemination Kit

“We’re A Pain-Management Company.” Nevro Adds SI Joint Surgery To SCS Business

MDR Changes Aren’t A ‘Catalyst’ For Medtech Investments In Ireland

eSTAR Now Open For PMA Submissions

See All
UsernamePublicRestriction

Register

MT126327

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By